Transgene (TNG.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $140.5M

Market Cap: $256.1MFounded: 1979HQ: Strasbourg, France

Sector Ranking#154 in Biologics / Biosimilars #53 in Cell & Gene Therapy

Overview

Transgene is a clinical-stage biotech focused on reshaping early-stage cancer treatment through its individualized neoantigen therapeutic vaccine (INTV) platform, myvac®. The company's lead asset, TG4050, is in Phase I/II trials for head and neck cancer, with promising early data suggesting potential to prevent relapse post-surgery. Under the leadership of industry veteran Alessandro Riva, Transgene has strategically pivoted to this high-potential niche, backed by financial visibility into early 2028, positioning it to advance a potentially transformative immunotherapy paradigm.

Oncology

Technology Platform

The myvac® platform is an integrated system for designing and manufacturing individualized neoantigen therapeutic vaccines (INTVs) using viral vectors (MVA/adenovirus) to stimulate a patient-specific T-cell response against cancer.

Funding History

5

Total raised:$140.5M

Debt$30MEuropean Investment BankJun 15, 2021

PIPE$25.5MUndisclosedJun 15, 2021

IPO$60MUndisclosedOct 15, 2000

Series A$25MMerieux DeveloppementJan 15, 2000

Opportunities

Transgene is targeting the high-value adjuvant therapy market for solid tumors, where preventing relapse represents a major unmet need.

Success with its lead asset TG4050 could validate its viral vector platform and unlock expansion into multiple other early-stage cancers, positioning the company in a rapidly growing segment of personalized oncology.

Risk Factors

Key risks include clinical failure of its lead candidate TG4050, the significant operational and cost challenges of scaling a personalized manufacturing platform, and intense competition from larger players with alternative vaccine technologies (e.g., mRNA).

The company's pre-revenue status and finite cash runway also pose financial risks.

Competitive Landscape

Transgene competes in the personalized cancer vaccine space against well-funded companies like BioNTech (mRNA with Genentech) and Moderna (mRNA with Merck). Its primary differentiation lies in its viral vector expertise, which may offer distinct immunogenic advantages, and its focused strategy on the early-stage, adjuvant treatment setting.